Table 1 |
||||||
|
Characteristics of countries. Source: OECD Health Data 2007 and EuroStat. All data for 2006 unless otherwise indicated. |
||||||
| Austria |
Finland |
Netherlands |
Sweden |
Denmark |
Portugal |
|
|
|
||||||
| Population (millions) (2006) |
8.27 |
5.26 |
16.33 |
9.05 |
5.43 |
10.57 |
| Population aged 65 and over (%) |
16.3 |
15.9 |
13.8 |
17.3 |
15.1 |
17.0 |
| GDP per capita (US Dollar) |
34 394 |
30 911 |
35 112 |
32 111 |
34 110 |
20 030 |
| Health expenditure as a share of GDP (%) |
10.2 |
7.5 |
9.2 |
9.1 |
9.1 |
10.2 |
| Pharmaceutical spending per capita (US Dollar PPP) |
409 |
380 |
318 |
351 |
276 |
445 |
| Pharmaceutical spending (% of GDP) |
1.2 |
1.2 |
1.0 |
1.1 |
0.8 |
2.2 |
| Automatic reimbursement for all marketed productsa |
No |
No |
No |
No |
No |
No |
| Pharmacoeconomic assessment required for reimbursement* |
Possibly |
Yes |
Only for innovative medicines |
Cost-effectiveness is one a criterion which determines reimbursement eligibility |
Not mandatory, sometimes used to justify a higher price |
Only for innovative medicines |
| Utilisation data source |
Claims data of the Austrian sickness fund (PEGASUS-SV) |
Ambulatory and hospital from the Finish National Agency for Medicines http://www.nam.fi |
Ambulatory data from the GIP database http://www.gipdatabank.nl |
Ambulatory data from Apoteket |
Ambulatory and hospital data from the Danish Medicines Agency http://www.medstat.dk |
Dispensing data of ambulatory care nationwide and IMS for hospital data (SIC-MED system) |
| Data type |
Reimbursement |
Dispensing |
Reimbursement |
Dispensing |
Dispensing |
Dispensing |
|
aPharmaceutical Pricing and Reimbursement Information (PPRI) report, the PPRI Network 2008. See http://ppri.oebig.at/ GDP: Gross Domestic Product | ||||||
Stolk et al. Orphanet Journal of Rare Diseases 2009 4:27 doi:10.1186/1750-1172-4-27 |
||||||
